2024
Mitochondrial heteroplasmy improves risk prediction for myeloid neoplasms
Hong Y, Pasca S, Shi W, Puiu D, Lake N, Lek M, Ru M, Grove M, Prizment A, Joshu C, Platz E, Guallar E, Arking D, Gondek L. Mitochondrial heteroplasmy improves risk prediction for myeloid neoplasms. Nature Communications 2024, 15: 10133. PMID: 39578475, PMCID: PMC11584845, DOI: 10.1038/s41467-024-54443-3.Peer-Reviewed Original ResearchConceptsClonal hematopoiesis of indeterminate potentialClonal hematopoiesisVariant allele fractionHeteroplasmic variantsIndeterminate potentialMyeloid neoplasmsHeteroplasmyMultiple mutationsAllele fractionMutationsHigh-risk groupPathogenic risk factorsMarkersRisk score modelDeleteriousnessSpliceosomeHematologic malignanciesRisk stratificationNeoplasm developmentNeoplasmsNeoplasm incidenceRisk factorsVariantsTERT promoter mutations and additional molecular alterations in thyroid fine-needle aspiration specimens: A multi-institutional study with histopathologic follow-up
Abi-Raad R, Shi Q, Chen F, Antony V, Hsiao W, Simsir A, Liu X, Brandler T, Cai G. TERT promoter mutations and additional molecular alterations in thyroid fine-needle aspiration specimens: A multi-institutional study with histopathologic follow-up. American Journal Of Clinical Pathology 2024, 163: 251-257. PMID: 39250709, DOI: 10.1093/ajcp/aqae117.Peer-Reviewed Original ResearchTERT promoter mutationsHistopathologic follow-upFine-needle aspirationTERT mutationsMolecular alterationsFollow-upPromoter mutationsThyroid carcinomaFine-needle aspiration diagnosisFine-needle aspiration specimensThyroid fine-needle aspiration specimensBenign thyroid neoplasmsSurgical follow-upAssociated with malignancyMulti-institutional studyThyroSeq v3Thyroid neoplasmsAspiration specimensTumor behaviorMalignant neoplasmsCarcinomaMalignancyNeoplasmsThyroidMutationsMixed-field ABO front typing as an early sign of disease recurrence in ABO-matched stem cell transplantation
Yurtsever N, Lee E, Pinatti L, Shah B, Tormey C, Siddon A. Mixed-field ABO front typing as an early sign of disease recurrence in ABO-matched stem cell transplantation. Immunohematology 2024, 40: 89-92. PMID: 39373301, PMCID: PMC11700658, DOI: 10.2478/immunohematology-2024-013.Peer-Reviewed Original ResearchConceptsStem cell transplantationCell transplantationDisease recurrenceMyeloid neoplasmsChimerism testingAllogeneic stem cell transplantationSigns of disease recurrenceIndicator of disease recurrenceDonor-recipient pairsABO antigen expressionGraft statusAntigen expressionFemale patientsPost-transplantationAllograft statusTransplantationABO typeRecurrenceClinical settingEarly signsNeoplasmsChimerismEarly indicatorABOEngraftmentTaste dysfunction after endoscopic endonasal resection of olfactory groove meningioma: Case series and review of the literature
Fecker A, Studer M, Manes R, Omay S, Detwiller K, Smith T, Andersen P, Sanusi O, Collins K, Geltzeiler M, Rimmer R. Taste dysfunction after endoscopic endonasal resection of olfactory groove meningioma: Case series and review of the literature. American Journal Of Otolaryngology 2024, 45: 104302. PMID: 38678798, DOI: 10.1016/j.amjoto.2024.104302.Peer-Reviewed Original ResearchResection of olfactory groove meningiomasOlfactory groove meningiomasEndoscopic endonasal resectionMinority of patientsSense of tasteTaste changesSeverity of symptomsOlfactory dysfunctionTaste dysfunctionMedian timeCase seriesClinical characteristicsOlfactory functionPatient counselingPatientsSense of smellAssociated with lateralizationResectionMeningiomasSurgeryDysfunctionRated severityNeoplasmsSurvey responsesAgeusiaThe Impact of Next-generation Sequencing on Interobserver Agreement and Diagnostic Accuracy of Desmoplastic Melanocytic Neoplasms
Chen A, Sharma N, Patel P, Olivares S, Bahrami A, Barnhill R, Blokx W, Bosenberg M, Busam K, de La Fouchardière A, Duncan L, Elder D, Ko J, Landman G, Lazar A, Lezcano C, Lowe L, Maher N, Massi D, Messina J, Mihic-Probst D, Parker D, Redpath M, Scolyer R, Shea C, Spatz A, Tron V, Xu X, Yeh I, Yun S, Zembowicz A, Gerami P. The Impact of Next-generation Sequencing on Interobserver Agreement and Diagnostic Accuracy of Desmoplastic Melanocytic Neoplasms. The American Journal Of Surgical Pathology 2024, 48: 708-718. PMID: 38590014, DOI: 10.1097/pas.0000000000002226.Peer-Reviewed Original ResearchConceptsDesmoplastic melanomaMelanocytic neoplasmsNext-generation sequencingInterobserver agreementDiagnostic accuracyHematoxylin and eosin sectionsImpact of next-generation sequencingDiagnostic scenariosMetastatic diseaseDesmoplastic tumorsMelanocytic tumorsMelanoma casesMelanoma geneticsFleiss' multirater kappaAccurate diagnosisNeoplasmsMelanomaAncillary toolDegree of improvementMultirater kappaDiagnosisGenomic findingsTumorGenome sequencing resultsPathologistsBRAF Mutated and Morphologically Spitzoid Tumors, a Subgroup of Melanocytic Neoplasms Difficult to Distinguish From True Spitz Neoplasms
Gerami P, Chen A, Sharma N, Patel P, Hagstrom M, Kancherla P, Geraminejad T, Olivares S, Biswas A, Bosenberg M, Busam K, de La Fouchardière A, Duncan L, Elder D, Ko J, Landman G, Lazar A, Lowe L, Massi D, Mihic-Probst D, Parker D, Scolyer R, Shea C, Zembowicz A, Yun S, Blokx W, Barnhill R. BRAF Mutated and Morphologically Spitzoid Tumors, a Subgroup of Melanocytic Neoplasms Difficult to Distinguish From True Spitz Neoplasms. The American Journal Of Surgical Pathology 2024, 48: 538-545. PMID: 38525831, DOI: 10.1097/pas.0000000000002194.Peer-Reviewed Original ResearchDNA Methylation Profiling Enables Accurate Classification of Nonductal Primary Pancreatic Neoplasms
Verschuur A, Hackeng W, Westerbeke F, Benhamida J, Basturk O, Selenica P, Raicu G, Molenaar I, van Santvoort H, Daamen L, Klimstra D, Yachida S, Luchini C, Singhi A, Geisenberger C, Brosens L. DNA Methylation Profiling Enables Accurate Classification of Nonductal Primary Pancreatic Neoplasms. Clinical Gastroenterology And Hepatology 2024, 22: 1245-1254.e10. PMID: 38382726, DOI: 10.1016/j.cgh.2024.02.007.Peer-Reviewed Original ResearchConceptsPancreatic neoplasmsMachine learning modelsAnalysis of biopsy specimensNonpancreatic neoplasmsNon-pancreatic originDiagnosis of pancreatic neoplasmsPrimary pancreatic neoplasmDiagnostic work-upArea under the curvePre-operative settingLearning modelsMethylation profilesPrimary tumorBiopsy specimensHistopathological diagnosisResected samplesDetecting neoplasmsDNA methylation signaturesTumor typesCancer entitiesLogistic regression modelsNeoplasmsClassifier performanceNeural networkConcordant classification
2023
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma
Gerson J, Handorf E, Villa D, Gerrie A, Chapani P, Li S, Medeiros L, Wang M, Cohen J, Churnetski M, Hill B, Sawalha Y, Hernandez-Ilizaliturri F, Kothari S, Vose J, Bast M, Fenske T, Gari S, Maddocks K, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns T, Donovan A, Wagner-Johnston N, Messmer M, Mehta A, Anderson J, Reddy N, Kovach A, Landsburg D, Glenn M, Inwards D, Ristow K, Karmali R, Kaplan J, Caimi P, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual J, Lue J, Diefenbach C, Fisher R, Barta S. Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma. Blood Advances 2023, 7: 7393-7401. PMID: 37874912, PMCID: PMC10758713, DOI: 10.1182/bloodadvances.2023010757.Peer-Reviewed Original ResearchConceptsProgression-free survivalMantle cell lymphomaOverall survivalPleomorphic variantMedian progression-free survivalB-cell non-Hodgkin lymphomaOutcomes of patientsAutologous hematopoietic transplantationNon-Hodgkin lymphomaComplete responsePatient characteristicsPoor prognosisHematopoietic transplantationCell lymphomaSecondary objectiveMonthsPatientsLymphomaSurvivalHigher scoresPrimary objectivePrognosisTransplantationNeoplasmsAre We Ready For “Triplet” Therapy in Higher-Risk MDS?
Brunner A, Platzbecker U, DeZern A, Zeidan A. Are We Ready For “Triplet” Therapy in Higher-Risk MDS? Clinical Hematology International 2023, 5: 23-32. PMID: 37933301, PMCID: PMC10625655, DOI: 10.46989/001c.88301.Peer-Reviewed Original ResearchAcute myeloid leukemiaCombination chemotherapyPatient populationOnly disease-modifying therapyNovel combination chemotherapyOngoing therapeutic challengeOlder patient populationUnique patient populationDisease-modifying therapiesCurrent treatment paradigmsTherapeutic challengeTreatment paradigmEffective therapyMyeloid leukemiaNew therapiesAppropriate endpointsTherapyChemotherapyComorbiditiesPatientsTransplantNeoplasmsLeukemiaPopulationDecitabineHistology Shift in Esophageal Cancer Between Biopsies and Resections After Neoadjuvant Therapy: A Pilot Study
Hou T, Yang Z, Zhang Q, Zhang X, Liao X, Lin J. Histology Shift in Esophageal Cancer Between Biopsies and Resections After Neoadjuvant Therapy: A Pilot Study. International Journal Of Surgical Pathology 2023, 32: 920-925. PMID: 37899731, DOI: 10.1177/10668969231208029.Peer-Reviewed Original ResearchNeoadjuvant therapyEsophageal adenocarcinomaNeuroendocrine neoplasmsNeuroendocrine carcinomaSurvival rateOverall median survival timeEsophageal neuroendocrine carcinomaPreoperative neoadjuvant therapyAdvanced esophageal adenocarcinomaMedian survival timeObserved survival ratesMainstay treatmentResidual adenocarcinomaConventional adenocarcinomaEsophageal cancerNeuroendocrine morphologyFocal positivitySurvival timeNeuroendocrine componentAdenocarcinomaBiopsyResectionSmall seriesPatientsNeoplasmsUpdates on risk stratification and management of lower-risk myelodysplastic syndromes/neoplasms
Badar T, Madanat Y, Zeidan A. Updates on risk stratification and management of lower-risk myelodysplastic syndromes/neoplasms. Future Oncology 2023, 19: 1877-1889. PMID: 37750305, DOI: 10.2217/fon-2023-0454.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsErythropoiesis-stimulating agentsTreatment-naive patientsHigh-risk patientsMeaningful efficacyIndolent courseDismal prognosisRandomized trialsRisk stratificationNeoplasm patientsSerial monitoringClinical trialsNovel therapiesPatientsAppropriate managementModest responseGood responseNeoplasmsTrialsNovel compoundsLuspaterceptLenalidomidePrognosisAnemiaTherapyMore needsRacial Disparities in Surgical Versus Nonsurgical Management of Distal Radius Fractures in a Medicare Population
Joo P, Halperin S, Dhodapkar M, Adeclat G, Elaydi A, Wilhelm C, Grauer J. Racial Disparities in Surgical Versus Nonsurgical Management of Distal Radius Fractures in a Medicare Population. Hand 2023, 20: 258-262. PMID: 37737570, PMCID: PMC11833841, DOI: 10.1177/15589447231198267.Peer-Reviewed Original ResearchDistal radius fracturesRace/ethnicityNonsurgical managementMultivariable analysisRadius fracturesMedicare populationIsolated distal radius fractureSurgical Versus Nonsurgical ManagementIndependent predictorsSurgical managementEquitable carePatientsFracture typeEthnic disparitiesSurgeryNational databaseRacial disparitiesComorbiditiesEthnicityFracturesDisparitiesManagementPolytraumaNeoplasmsPopulationClassification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)
Stahl M, Bewersdorf J, Xie Z, Porta M, Komrokji R, Xu M, Abdel-Wahab O, Taylor J, Steensma D, Starczynowski D, Sekeres M, Sanz G, Sallman D, Roboz G, Platzbecker U, Patnaik M, Padron E, Odenike O, Nimer S, Nazha A, Majeti R, Loghavi S, Little R, List A, Kim T, Hourigan C, Hasserjian R, Halene S, Griffiths E, Gore S, Greenberg P, Figueroa M, Fenaux P, Efficace F, DeZern A, Daver N, Churpek J, Carraway H, Buckstein R, Brunner A, Boultwood J, Borate U, Bejar R, Bennett J, Wei A, Santini V, Savona M, Zeidan A. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). Blood Reviews 2023, 62: 101128. PMID: 37704469, DOI: 10.1016/j.blre.2023.101128.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsInternational consensus classificationResponse assessmentWorld Health Organization classificationPatient-centered careRisk assessment toolClinical outcomesRisk stratificationOrganization classificationCentered careTherapeutic benefitTherapeutic outcomesConsensus classificationResponse criteriaInternational ConsortiumNeoplasmsLife assessmentAssessment toolOutcomesReportAssessmentPrognosticationCareTreatment Considerations of Myelodysplastic Syndromes/Neoplasms for Pathologists
Madanat Y, Zeidan A. Treatment Considerations of Myelodysplastic Syndromes/Neoplasms for Pathologists. Clinics In Laboratory Medicine 2023, 43: 685-698. PMID: 37865511, DOI: 10.1016/j.cll.2023.07.003.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBone marrow biopsy reportsAvailable treatment optionsBest therapeutic approachClinical presentationPathologic findingsRisk stratificationTherapeutic optionsTreatment optionsBiopsy reportsDisease entityTherapeutic approachesTreatment considerationsAccurate diagnosisGenetic abnormalitiesDiagnosisDisease subclassificationPatientsNeoplasmsHematopathologistsOptionsPrognosticationAbnormalitiesCliniciansSubclassificationMolecular findings in myeloid neoplasms
Tran T, Siddon A. Molecular findings in myeloid neoplasms. International Journal Of Laboratory Hematology 2023, 45: 442-448. PMID: 37345257, DOI: 10.1111/ijlh.14118.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMyeloid neoplasmsNext-generation sequencingMyeloproliferative neoplasmsInternational diagnostic guidelinesSomatic gene mutationsHematologic cancersMyeloid leukemiaDiagnostic guidelinesClinical relevanceMyeloid disordersPatient careNeoplasmsCytogenetic findingsMolecular findingsGene mutationsNew molecular technologiesMolecular technologiesMutationsLeukemiaCancerPrognosticationCliniciansFindingsModifier mutationsMalignant blue nevus: Characterization of US epidemiology and prognostic factors of a rare neoplasm with aggressive clinical course using the Surveillance, Epidemiology, and End Results Program database
Yumeen S, Mirza F, Mirza H, Zogg C, Leventhal J, Cohen J. Malignant blue nevus: Characterization of US epidemiology and prognostic factors of a rare neoplasm with aggressive clinical course using the Surveillance, Epidemiology, and End Results Program database. Journal Of The American Academy Of Dermatology 2023, 89: 843-846. PMID: 37343827, DOI: 10.1016/j.jaad.2023.05.090.Peer-Reviewed Original ResearchSpectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms
Xie Z, Chen E, Mendez L, Komrokji R, Zeidan A. Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms. The Cancer Journal 2023, 29: 130-137. PMID: 37195768, DOI: 10.1097/ppo.0000000000000656.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsClonal hematopoiesisHigh-risk patientsRisk of progressionSuch patientsUndetermined significanceAge-related diseasesHematologic malignanciesClonal cytopeniaMyeloid neoplasmsHigh riskUnmet needMyeloid malignanciesNatural historyCH managementPatientsMalignancySignificant knowledge gapsRiskHematopoiesisCytopeniasNeoplasmsSyndromeSurveillance of Pancreatic Cystic Neoplasms
Chhoda A, Schmidt J, Farrell J. Surveillance of Pancreatic Cystic Neoplasms. Gastrointestinal Endoscopy Clinics Of North America 2023, 33: 613-640. PMID: 37245939, DOI: 10.1016/j.giec.2023.03.010.Peer-Reviewed Original ResearchConceptsPancreatic cystic neoplasmsAdvanced neoplasiaCystic neoplasmsIntraductal papillary mucinous neoplasmClinical surveillance guidelinesHigh-risk morphologyConsensus clinical guidelinesPapillary mucinous neoplasmAccurate preoperative diagnosisCross-sectional imagingSurgical resectionSurgical indicationsPreoperative diagnosisSurveillance guidelinesSurveillance intervalsMucinous neoplasmsMalignant potentialClinical evaluationClinical guidelinesPancreatic cystsClinical challengeSurveillance strategiesNeoplasmsNeoplasiaCurrent conceptsWhat’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach
Awada H, Gurnari C, Xie Z, Bewersdorf J, Zeidan A. What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach. Cancers 2023, 15: 2248. PMID: 37190176, PMCID: PMC10137017, DOI: 10.3390/cancers15082248.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAcute myeloid leukemiaMDS/AML patientsEarly clinical trialsPotential therapeutic agentAML patientsMultidrug combinationsClinical trialsMyeloid leukemiaMyeloid neoplasmsRational approachSingle agentCurrent managementTherapeutic potentialStandardized guidelinesTherapeutic agentsMutational characteristicsPatientsNeoplasmsLatest findingsGenomic factorsCellular adaptationAgentsHMA resistanceFailureLeukemiaCurrent landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)
Bewersdorf J, Xie Z, Bejar R, Borate U, Boultwood J, Brunner A, Buckstein R, Carraway H, Churpek J, Daver N, Porta M, DeZern A, Fenaux P, Figueroa M, Gore S, Griffiths E, Halene S, Hasserjian R, Hourigan C, Kim T, Komrokji R, Kuchroo V, List A, Loghavi S, Majeti R, Odenike O, Patnaik M, Platzbecker U, Roboz G, Sallman D, Santini V, Sanz G, Sekeres M, Stahl M, Starczynowski D, Steensma D, Taylor J, Abdel-Wahab O, Xu M, Savona M, Wei A, Zeidan A. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). Blood Reviews 2023, 60: 101072. PMID: 36934059, DOI: 10.1016/j.blre.2023.101072.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsImmune checkpoint inhibitorsSpecific molecular alterationsNovel animal modelInnate immune systemCheckpoint inhibitorsImmune dysregulationMDS patientsClinical trialsNovel therapiesTherapeutic strategiesAnimal modelsGermline predispositionImmune systemMolecular alterationsClinical researchInternational ConsortiumNeoplasmsClinical workGenetic landscapeInternational WorkshopPatientsCurrent landscapePathogenesisTherapyDisease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply